search
Back to results

Normal Versus Dual Wave Insulin Bolus for High-protein Food

Primary Purpose

Type 1 Diabetes

Status
Completed
Phase
Phase 4
Locations
Poland
Study Type
Interventional
Intervention
insulin aspart
insulin lispro
insulin glulisine
Sponsored by
Medical University of Warsaw
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Type 1 Diabetes focused on measuring dual-wave bolus, square bolus, normal bolus, standard bolus, high-protein meal, prandial insulin requirement

Eligibility Criteria

10 Years - 18 Years (Child, Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • duration of type 1 diabetes longer than 12 months
  • insulin pump therapy longer than 3 months
  • written informed consent by patients and parents
  • patients must be willing to wear a glucose sensor for two days
  • insulin requirement more than 0,5 units/kg/day

Exclusion Criteria:

  • concomitant dietary restrictions (e.g. celiac disease or food allergy)
  • diabetes related complications (e.g. nephropathy)
  • any disease judged by the investigator to affect the trial
  • withdrawal of consent to participate in the study

Sites / Locations

  • Department of Pediatrics, Medical University of Warsaw, Poland

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Normal/ Dual-wave

Dual-wave/Normal

Arm Description

On the first study day, pre-breakfast insulin was given as a normal bolus 15 minutes before a standardized high-protein meal. On the second day, pre-breakfast insulin was given as a dual-wave bolus before the same high-protein meal. The carbo-insulin and fat-protein-insulin ratio on both study days were identical to the patient's ratio when entering trial. Kind of study bolus insulin will be a rapid-acting insulin analog same as previously used by the participant (before entering the trial) - insulin aspart, insulin lispro or insulin glulisine

On the first study day, pre-breakfast insulin was given as a dual-wave bolus 15 minutes before a standardized high-protein meal. On the second day, pre-breakfast insulin was given as a normal bolus before the same high-protein meal. The carbo-insulin and fat-protein-insulin ratio on both study days were identical to the patient's ratio when entering trial. Kind of study bolus insulin will be a rapid-acting insulin analog same as previously used by the participant (before entering the trial) - insulin aspart, insulin lispro or insulin glulisine

Outcomes

Primary Outcome Measures

Postprandial glycemia
Post-prandial blood glucose excursions measured by self monitoring of blood glucose (SMBG)
Postprandial glycemia
Post-prandial blood glucose excursions measured by self monitoring of blood glucose
Postprandial glycemia
Post-prandial blood glucose excursions measured by self monitoring of blood glucose

Secondary Outcome Measures

Hypoglycemia episodes
Hypoglycemia defined as a plasma glucose concentration below 65 mg/dl with or without symptoms
Glucose Area Under the Curve (AUC)
measurements based on CGMS
Mean amplitude of glycemic excursion
measurements based on CGMS

Full Information

First Posted
October 7, 2014
Last Updated
January 29, 2018
Sponsor
Medical University of Warsaw
search

1. Study Identification

Unique Protocol Identification Number
NCT02276859
Brief Title
Normal Versus Dual Wave Insulin Bolus for High-protein Food
Official Title
The Optimal Type of Bolus Following a High-protein Meal in Type 1 Diabetic Children Treated With Insulin Pumps
Study Type
Interventional

2. Study Status

Record Verification Date
September 2014
Overall Recruitment Status
Completed
Study Start Date
October 2014 (Actual)
Primary Completion Date
September 2015 (Actual)
Study Completion Date
September 2015 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Medical University of Warsaw

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Patients receive a standardized high-protein test meal at breakfast time. Insulin is given as bolus (normal or dual-wave (normal plus square) and basal rate using an insulin pump. The 3h post-meal glucose excursions will be recorded by self-blood glucose measurements (SMBG) (every 1 hour) and continuous glucose monitoring system (CGMS). The intervention is taking part under in-patient clinical conditions.
Detailed Description
The dual-wave bolus delivers an immediate normal pre-meal insulin bolus followed by square-wave bolus that is evenly delivered over several hours as programmed by the patient. The aim of this study is to compare post-prandial glycaemic excursions following a high-protein meal after administration of insulin by normal vs dual-wave bolus. During this prospective, cross-over, repeated measures study, pediatric patients with type 1 diabetes, treated with insulin pump therapy will be evaluated using the self-blood glucose measurements following standardized high-protein meal and two types of boluses (normal or dual-wave). The required insulin dose will be calculated based on patient's insulin-exchange ratio. A high-protein meal will be given on two subsequent breakfasts and comparisons will be made between normal and dual-wave insulin bolus delivery. Prolonged post-prandial glycaemic excursions will be identified using the CGMS.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 1 Diabetes
Keywords
dual-wave bolus, square bolus, normal bolus, standard bolus, high-protein meal, prandial insulin requirement

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Crossover Assignment
Masking
Investigator
Allocation
Randomized
Enrollment
70 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Normal/ Dual-wave
Arm Type
Experimental
Arm Description
On the first study day, pre-breakfast insulin was given as a normal bolus 15 minutes before a standardized high-protein meal. On the second day, pre-breakfast insulin was given as a dual-wave bolus before the same high-protein meal. The carbo-insulin and fat-protein-insulin ratio on both study days were identical to the patient's ratio when entering trial. Kind of study bolus insulin will be a rapid-acting insulin analog same as previously used by the participant (before entering the trial) - insulin aspart, insulin lispro or insulin glulisine
Arm Title
Dual-wave/Normal
Arm Type
Experimental
Arm Description
On the first study day, pre-breakfast insulin was given as a dual-wave bolus 15 minutes before a standardized high-protein meal. On the second day, pre-breakfast insulin was given as a normal bolus before the same high-protein meal. The carbo-insulin and fat-protein-insulin ratio on both study days were identical to the patient's ratio when entering trial. Kind of study bolus insulin will be a rapid-acting insulin analog same as previously used by the participant (before entering the trial) - insulin aspart, insulin lispro or insulin glulisine
Intervention Type
Drug
Intervention Name(s)
insulin aspart
Other Intervention Name(s)
NovoRapid®
Intervention Description
A kind of study bolus insulin will be insulin aspart if participant used insulin aspart before entering the trial
Intervention Type
Drug
Intervention Name(s)
insulin lispro
Other Intervention Name(s)
Humalog®
Intervention Description
A kind of study bolus insulin will be insulin lispro if participant used insulin lispro before entering the trial
Intervention Type
Drug
Intervention Name(s)
insulin glulisine
Other Intervention Name(s)
Apidra®
Intervention Description
A kind of study bolus insulin will be insulin glulisine if participant used insulin glulisine before entering the trial
Primary Outcome Measure Information:
Title
Postprandial glycemia
Description
Post-prandial blood glucose excursions measured by self monitoring of blood glucose (SMBG)
Time Frame
60 minutes after the meal
Title
Postprandial glycemia
Description
Post-prandial blood glucose excursions measured by self monitoring of blood glucose
Time Frame
120 minutes after the meal
Title
Postprandial glycemia
Description
Post-prandial blood glucose excursions measured by self monitoring of blood glucose
Time Frame
180 minutes after the meal
Secondary Outcome Measure Information:
Title
Hypoglycemia episodes
Description
Hypoglycemia defined as a plasma glucose concentration below 65 mg/dl with or without symptoms
Time Frame
3-hour study period
Title
Glucose Area Under the Curve (AUC)
Description
measurements based on CGMS
Time Frame
3-hour study period
Title
Mean amplitude of glycemic excursion
Description
measurements based on CGMS
Time Frame
3-hour study period

10. Eligibility

Sex
All
Minimum Age & Unit of Time
10 Years
Maximum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: duration of type 1 diabetes longer than 12 months insulin pump therapy longer than 3 months written informed consent by patients and parents patients must be willing to wear a glucose sensor for two days insulin requirement more than 0,5 units/kg/day Exclusion Criteria: concomitant dietary restrictions (e.g. celiac disease or food allergy) diabetes related complications (e.g. nephropathy) any disease judged by the investigator to affect the trial withdrawal of consent to participate in the study
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Agnieszka Szypowska
Organizational Affiliation
University of Alberta
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Katarzyna Piechowiak
Organizational Affiliation
University of Alberta
Official's Role
Principal Investigator
Facility Information:
Facility Name
Department of Pediatrics, Medical University of Warsaw, Poland
City
Warsaw
ZIP/Postal Code
01-184
Country
Poland

12. IPD Sharing Statement

Learn more about this trial

Normal Versus Dual Wave Insulin Bolus for High-protein Food

We'll reach out to this number within 24 hrs